The come-up is more often characterized by negatively valenced feeling states that resemble an acute stress reaction, while the come-down phase is more often characterized by positively valenced feeling states of the sort often observed following recovery from illness or resolution of stress.

In a bid to increase accessibility, a new study by the Australian National University (ANU) School of Medicine and Psychology will look into the viability of the application of psychedelics in a group setting. The study will focus on the psychological, cognitive and physical effects, including adverse events, of taking psilocybin and MDMA in a group setting.

If MDMA receives FDA approval this autumn (which seems very likely), then the UK Medicines & Healthcare products Regulatory Agency (MHRA) will recognise MDMA within either a 60-day or 110-day timeline. Since the UK has already given MDMA an approval-speeding Innovation Passport, it seems likely that MDMA licensing will follow the 60-day timeline, leading to UK licensing by the end of the year or not long after. Lots of fingers crossed!